PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
DreamCIS is showing a recovering operating profit trend in its core contract research organization (CRO) business, while derivative valuation swings tied to a convertible bond and equity investments are causing large fluctuations in net income.
Consolidated revenue rose for three straight years from KRW 38.8 billion in 2022 to KRW 66.6 billion in 2025, while the operating margin, which fell to 3.3% in 2023, recovered to around 8% in 2024-2025.
The largest shareholder is Tigermed (Hong Kong Tigermed), China's top CRO and one of the global top ten, whose network supports multi-regional clinical trial orders.
In January 2026 the company completed a controlling-stake acquisition of U.S. organoid firm Curi Bio, expanding into non-clinical and animal-testing-alternative business.
Derivative valuation swings on a convertible bond issued in September 2025 have created a persistent gap between operating profit and net income from Q4 2025 through Q2 2026.
The debt-to-equity ratio jumped from 54.8% in 2024 to 88.6% in 2025, warranting attention to changes in the balance sheet structure.
DreamCIS is a contract research organization (CRO) founded in 2000 and listed on KOSDAQ in 2020, providing services covering the entire drug development process for pharmaceutical companies and biotech ventures.
Its service lineup spans Phase 1-3 clinical trials, post-marketing surveillance, clinical quality management, data management, statistical analysis, and regulatory strategy consulting. The largest shareholder is Tigermed (Hong Kong Tigermed), China's top CRO and one of the global top ten, holding roughly a 59% stake.
The company leverages Tigermed's global network to support both Korean firms expanding overseas and global firms running multi-regional clinical trials (MRCT) in Korea.
Its subsidiaries include MediTip, one of Korea's largest drug and medical device regulatory consulting firms, and LCS, a non-clinical brokerage and consulting specialist, both of which have contributed revenue and profit since being consolidated.
In January 2026 the company completed a controlling-stake acquisition of Curi Bio, a Seattle-based organoid technology firm, extending its portfolio into clinical, non-clinical, regulatory, and organoid businesses.
Curi Bio holds cardiac and skeletal-muscle organoid technology and counts global pharma majors such as Eli Lilly and Novo Nordisk among its customers.
In Korea's listed CRO sector, competitors include non-clinical-focused ChemOn (Coastem ChemOn), Biotoxtech, and Woojung Bio, as well as clinical-focused Bioinfra and CNR Research.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩16.6B | ₩1.5B | 9.1% |
| 2025Q3 | ₩16.5B | ₩2.8B | 16.9% |
| 2025Q4 | ₩19.3B | -₩400M | −2.0% |
| 2026Q1 | ₩17.4B | ₩500M | 3.1% |
| 2026Q2 | ₩20B | ₩2.3B | 11.3% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩38.9B | ₩5.8B | ₩4.4B | 15.0% | 9.0% | 54.6% |
| 2023 | ₩47.8B | ₩1.6B | ₩3.7B | 3.3% | 6.8% | 55.7% |
| 2024 | ₩58.7B | ₩5.1B | ₩5.3B | 8.6% | 7.8% | 54.8% |
| 2025 | ₩66.6B | ₩5.2B | ₩7.1B | 7.9% | 9.3% | 88.6% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue rose for three consecutive years, from KRW 38.8 billion in 2022 to KRW 47.8 billion in 2023, KRW 58.7 billion in 2024, and KRW 66.6 billion in 2025. The operating margin fell sharply from 15.0% in 2022 to 3.3% in 2023, then recovered to 8.6% in 2024 and 7.9% in 2025.
Net income attributable to owners dipped to KRW 4.4 billion in 2022 and KRW 3.7 billion in 2023 before recovering to KRW 5.3 billion in 2024 and KRW 7.1 billion in 2025, showing a clear earnings recovery on an annual basis. Quarterly trends, however, have been far less smooth.
In Q3 2025 operating profit reached KRW 2.8 billion while owner net income jumped to KRW 13.4 billion, only for the trend to reverse in Q4 2025, when the company posted an operating loss of KRW 0.4 billion and an owner net loss of KRW 8.6 billion.
This reflects derivative valuation swings on a KRW 15 billion convertible bond issued in September 2025 along with changes in the fair value of equity investments; the company disclosed in February 2026 that the cumulative valuation loss had reached KRW 8.15 billion, equal to 10.13% of equity.
Into 2026, the core business stayed profitable with operating profit of KRW 0.5 billion in Q1 and KRW 2.3 billion in Q2, yet owner net income was negative in both quarters (KRW -0.1 billion and KRW -4.3 billion), extending the gap between operating profit and net income.
According to FnGuide, cumulative nine-month 2025 revenue, operating profit, and net income rose 7.8%, 140.2%, and 546.8% year-on-year, respectively, showing that both core-business growth and investment-related gains were reflected simultaneously.
One outlet's analysis of first-half 2026 filings assessed that DreamCIS maintained solid top-line growth and an operating-profit-positive trend.
Korea's clinical trial market is expected to keep growing on the back of high-quality infrastructure and a clear regulatory framework, and the government is pursuing a KRW 25 trillion pharma-bio R&D investment plan for 2023-2027 with strategic CRO support aimed at reaching global third place.
Growing preference among global pharma companies for running trials in Korea is expanding demand for research outsourcing, while multinational trial orders and expanded projects from Chinese pharma clients via the Tigermed network are contributing to revenue growth.
In the non-clinical segment, the spread of animal-testing-alternative regulations is creating new demand: the U.S. FDA Modernization Act 2.0 and 3.0 are easing mandatory animal-testing requirements for new drug approvals, and a related bill has been introduced in Korea's National Assembly.
Against this backdrop, organoids are emerging as an alternative that can lower clinical failure rates and costs by providing data more accurate than animal testing.
Listed domestic CRO peers include non-clinical-focused ChemOn (Coastem ChemOn), Biotoxtech, Woojung Bio, and HBL Biostep, alongside clinical-focused Bioinfra and CNR Research.
Korea's Ministry of Food and Drug Safety selected DreamCIS as a co-participating institution in a five-year (2026-2030) data-science-based regulatory science talent development program, a move interpreted as reflecting the company's real-world data (RWD) and real-world evidence (RWE) capabilities.
Shinhan Investment forecast in a January 16, 2026 report newly initiated revenue of KRW 89.0 billion and operating profit of KRW 10.8 billion for 2026, an estimate that has not yet been confirmed and needs to be checked against actual quarterly results going forward.
The same report expected bridge-trial demand from Chinese listed biotechs to increasingly contribute to growth from 2026.
Following the completion of the Curi Bio control acquisition, the company has dispatched staff to Curi Bio's Seattle headquarters and is pursuing the establishment of a Curi Bio Korea entity to integrate domestic and overseas operations.
Recent industry reports indicated that the company received approval for a domestic Phase 3 clinical trial plan (IND) for the GLP-1 class obesity drug candidate BGM0504.
According to one media report, subsidiary MediTip raised roughly KRW 10 billion in funding led by Temasek, which is expected to expand its regulatory consulting business.
Shinhan Investment listed checkpoints to monitor going forward, including the pace of global bridge-trial order wins, the share of high-value-added projects, continued earnings growth at Curi Bio, and changes in the value of investment assets.
Over the most recent four quarters (Q3 2025 through Q2 2026), operating profit stayed positive in most periods, but repeated derivative valuation swings on the convertible bond and changes in equity-investment fair value flowing into net income have created a notable gap between operating-profit-based and net-income-based valuation multiples.
As a result, the earnings multiple calculated on trailing four-quarter net income sits well above the multi-year average trading band, whereas the gap narrows considerably when measured against operating profit alone.
In terms of the relationship between share price and net assets, the current price appears to carry a modest premium over book value. The company has not paid dividends in recent years, so its share price behavior appears to be driven more by growth and structural narratives than by dividend appeal.
Overall, this stock's valuation can be seen as more sensitive to the direction of non-operating gains and losses and to swings in investment-asset value than to the underlying operating business alone.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Revenue has grown for four consecutive years and the operating margin rebounded after bottoming in 2023. Multi-regional trial orders via the Tigermed network and expanding projects from Chinese biotechs continue to support core-business growth.
Operating profit stayed positive in both Q1 and Q2 2026, underscoring the underlying strength of the core business.
The Curi Bio acquisition gave the company entry into the animal-testing-alternative field, and Curi Bio already counts global pharma majors such as Eli Lilly and Novo Nordisk among its customers.
Ongoing moves in the U.S. and Korea to ease animal-testing rules or introduce alternative testing methods are broadening the demand base for organoid-related services.
Regulatory and non-clinical consulting subsidiaries such as MediTip and LCS have each generated profit and contributed to consolidated results since being folded in.
The company also continues to hold equity stakes in numerous biotech ventures, providing an additional avenue for profit realization beyond the core CRO business.
Derivative valuation losses on the convertible bond pushed net income into negative territory in Q4 2025 and both Q1 and Q2 2026, even as operating profit remained positive.
The cumulative valuation loss disclosed by the company already exceeds 10% of equity, and further valuation swings remain possible depending on how bond conditions evolve.
The debt-to-equity ratio rose sharply from 54.8% in 2024 to 88.6% in 2025. This reflects the convertible bond issuance and related liabilities, and the capital structure could shift again depending on future conversion or redemption terms.
The company has completed multiple acquisitions in the past two years, including MediTip, LCS, and Curi Bio, rapidly expanding its business scope. This creates a burden of integrating several organizations at once, alongside ongoing governance and dealflow dependence on largest shareholder Tigermed.
Valuation swings on the convertible bond's embedded derivative are causing large fluctuations in quarterly net income, and further gains or losses could occur depending on share price or bond term changes. The debt-to-equity ratio also rose sharply within a year, warranting monitoring of financial leverage.
A series of acquisitions—MediTip, LCS, and Curi Bio—has increased the burden of organizational and systems integration. Setting up Curi Bio Korea and dispatching personnel could generate near-term integration costs, and delayed integration could postpone expected synergies.
Clinical trial orders are influenced by domestic and global biotech funding cycles and the progress of drug-development pipelines.
Animal-testing-alternative regulations are still at an early legislative stage, so the demand trajectory for the organoid business could vary depending on the pace of adoption in each country.
The filing deadline for the Q3 2026 quarterly report, a point to check whether the operating profit trend continues and whether further convertible-bond derivative valuation effects appear.
It will be worth checking how much the organoid segment, following Curi Bio's consolidation, contributes to revenue and earnings in the consolidated results.
The progress of the domestic Phase 3 trial for GLP-1 class obesity candidate BGM0504 and any related order expansion should be monitored.
It is worth tracking the outcomes of participation in MFDS's global regulatory science talent development program and whether it leads to new regulatory or data-science-related revenue.
Investors should watch for potential capital structure changes such as conversion price adjustments or exercise of early redemption (put) rights on the remaining convertible bond.
DreamCIS has shown steady multi-year growth in revenue and operating profit within its core CRO business, and the Curi Bio acquisition, combined with Tigermed's global network, has added organoid-related expansion as a new growth axis.
However, derivative valuation swings on the convertible bond issued in September 2025 have significantly affected net income for four consecutive quarters, sustaining a gap between operating profit and net income.
The sharp rise in the debt-to-equity ratio within a year and the burden of integrating several concurrent acquisitions are also points worth watching. Some brokerages, including Shinhan Investment, have forecast growth in 2026 revenue and operating profit, but these remain unconfirmed estimates.
Investors should distinguish between the improving trend in core operating profit and the volatility in non-operating gains and losses, and it will be important to track upcoming quarterly results and convertible-bond-related disclosures to see how the underlying earnings structure stabilizes.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.